{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:34:42Z","timestamp":1777581282819,"version":"3.51.4"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/jcp.0b013e31827d145a","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T12:27:12Z","timestamp":1356956832000},"page":"11-17","source":"Crossref","is-referenced-by-count":44,"title":["Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients"],"prefix":"10.1097","volume":"33","author":[{"given":"Arun K.","family":"Tiwari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva J.","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Likhodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement C.","family":"Zai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret K.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.177.1.4","article-title":". Stigmatisation of people with mental illnesses.","volume":"177","author":"Crisp","year":"2000","journal-title":"Br J Psychiatry"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":". Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2710.2009.01084.x","article-title":". Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study.","volume":"35","author":"Gebhardt","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00041444-200512000-00011","article-title":". Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs.","volume":"15","author":"Theisen","year":"2005","journal-title":"Psychiatr Genet"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.psychres.2004.02.018","article-title":". Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation.","volume":"133","author":"Wehmeier","year":"2005","journal-title":"Psychiatry Res"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/mp.2011.109","article-title":". Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.","volume":"17","author":"Lett","year":"2012","journal-title":"Mol Psychiatry"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design.","volume":"127","author":"Coccurello","year":"2010","journal-title":"Pharmacol Ther"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","article-title":". Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.","volume":"27","author":"Kluge","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/oby.2008.277","article-title":". Adiposity and eating behaviors in patients under second generation antipsychotics.","volume":"16","author":"Blouin","year":"2008","journal-title":"Obesity (Silver Spring)"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1017\/S0033291710001893","article-title":". The heterogeneity of antipsychotic response in the treatment of schizophrenia.","volume":"41","author":"Case","year":"2011","journal-title":"Psychol Med"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.lfs.2011.02.014","article-title":". Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats.","volume":"88","author":"Shobo","year":"2011","journal-title":"Life Sci"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2010.05.009","article-title":". Olanzapine affects locomotor activity and meal size in male rats.","volume":"97","author":"van der Zwaal","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.physbeh.2011.05.033","article-title":"Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.","volume":"104","author":"Teff","year":"2011","journal-title":"Physiol Behav"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0006-8993(85)90730-9","article-title":". An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat.","volume":"331","author":"Bai","year":"1985","journal-title":"Brain Res"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.npep.2004.05.005","article-title":"NPY and Y receptors: lessons from transgenic and knockout models.","volume":"38","author":"Lin","year":"2004","journal-title":"Neuropeptides"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","article-title":". Central nervous system control of food intake.","volume":"404","author":"Schwartz","year":"2000","journal-title":"Nature"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MED.0b013e3283422f0a","article-title":"Neuropeptide Y and peptide YY: important regulators of energy metabolism.","volume":"18","author":"Nguyen","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2011.03.011","article-title":"The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer.","volume":"131","author":"Zhang","year":"2011","journal-title":"Pharmacol Ther"},{"key":"R19-3-20210128","first-page":"869","article-title":"Y eat Nutrition.","volume":"24","author":"Chee","year":"2008","journal-title":""},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00213-008-1415-1","article-title":". Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.","volume":"203","author":"Davoodi","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbr.2009.09.032","article-title":"Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance.","volume":"207","author":"Guesdon","year":"2010","journal-title":"Behav Brain Res"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.npep.2006.01.002","article-title":"Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats.","volume":"40","author":"Huang","year":"2006","journal-title":"Neuropeptides"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000245220","article-title":". Risperidone treatment increases CB1 receptor binding in rat brain.","volume":"91","author":"Secher","year":"2010","journal-title":"Neuroendocrinology"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0269881106061199","article-title":"Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus.","volume":"20","author":"Kirk","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","article-title":". Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation.","volume":"6","author":"Ferno","year":"2011","journal-title":"PLoS One"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.","volume":"59","author":"Martins","year":"2010","journal-title":"Diabetes"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1017\/S1461145711001556","article-title":". Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response.","volume":"15","author":"Nikisch","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1463-1326.2009.01193.x","article-title":". Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.","volume":"12","author":"Zhang","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/4027","article-title":". Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels.","volume":"4","author":"Karvonen","year":"1998","journal-title":"Nat Med"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3109\/07853899809002597","article-title":". Neuropeptide Y: a novel link between the neuroendocrine system and cholesterol metabolism.","volume":"30","author":"Uusitupa","year":"1998","journal-title":"Ann Med"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2007.10.003","article-title":". Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.","volume":"98","author":"de Leon","year":"2008","journal-title":"Schizophr Res"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.ijo.0802067","article-title":"Association analysis of genes involved in the leptin-signaling pathway with obesity in Brazil.","volume":"26","author":"Mattevi","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/sj.ijo.0803314","article-title":". Polymorphisms in the NPY and AGRP genes and body fatness in Dutch adults.","volume":"30","author":"van Rossum","year":"2006","journal-title":"Int J Obes (Lond)"},{"key":"R34-3-20210128","doi-asserted-by":"crossref","first-page":"E2055","DOI":"10.1210\/jc.2011-0195","article-title":". Polymorphisms in the neuropeptide Y gene and the risk of obesity: findings from two prospective cohorts.","volume":"96","author":"Yeung","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-3-20210128","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1055\/s-2005-865650","article-title":". Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men.","volume":"113","author":"Nordman","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.regpep.2007.08.028","article-title":"NPY L7P polymorphism and metabolic diseases.","volume":"149","author":"Pesonen","year":"2008","journal-title":"Regul Pept"},{"key":"R37-3-20210128","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nature06858","article-title":". Genetic variation in human NPY expression affects stress response and emotion.","volume":"452","author":"Zhou","year":"2008","journal-title":"Nature"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0304-3940(03)00718-3","article-title":". Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans.","volume":"347","author":"Itokawa","year":"2003","journal-title":"Neurosci Lett"},{"key":"R39-3-20210128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbadis.2004.06.023","article-title":". A high proportion of polymorphisms in the promoters of brain expressed genes influences transcriptional activity.","volume":"1690","author":"Buckland","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"R40-3-20210128","doi-asserted-by":"crossref","first-page":"E1594","DOI":"10.1002\/humu.21299","article-title":". Human NPY promoter variation rs16147:T C as a moderator of prefrontal NPY gene expression and negative affect.","volume":"31","author":"Sommer","year":"2010","journal-title":"Hum Mutat"},{"key":"R41-3-20210128","doi-asserted-by":"crossref","first-page":"e1000318","DOI":"10.1371\/journal.pgen.1000318","article-title":". Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis.","volume":"5","author":"Shah","year":"2009","journal-title":"PLoS Genet"},{"key":"R42-3-20210128","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.mp.4001944","article-title":". Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.","volume":"12","author":"Ruano","year":"2007","journal-title":"Mol Psychiatry"},{"key":"R43-3-20210128","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/npp.2009.235","article-title":". A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia.","volume":"35","author":"Tiwari","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R44-3-20210128","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.pnpbp.2010.08.009","article-title":". Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients.","volume":"34","author":"Tiwari","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R45-3-20210128","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1093\/nar\/19.19.5444","article-title":"A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies.","volume":"19","author":"Lahiri","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gepi.10252","article-title":"Pedigree disequilibrium tests for multilocus haplotypes.","volume":"25","author":"Dudbridge","year":"2003","journal-title":"Genet Epidemiol"},{"key":"R47-3-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":". Haploview: analysis and visualization of LD and haplotype maps.","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"R48-3-20210128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1086\/383251","article-title":"A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.","volume":"74","author":"Nyholt","year":"2004","journal-title":"Am J Hum Genet"},{"key":"R50-3-20210128","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1093\/bioinformatics\/btq352","article-title":". mbmdr: An R package for exploring gene-gene interactions associated with binary or quantitative traits.","volume":"26","author":"Calle","year":"2010","journal-title":"Bioinformatics"},{"key":"R51-3-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/archgenpsychiatry.2010.197","article-title":". Emotion processing, major depression, and functional genetic variation of neuropeptide Y.","volume":"68","author":"Mickey","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"R52-3-20210128","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/hup.519","article-title":". The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.","volume":"18","author":"Fitzgerald","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"R53-3-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1359786806066040","article-title":"The 5-HT2C receptor and antipsychotic-induced weight gainmechanisms and genetics.","volume":"20","author":"Reynolds","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R54-3-20210128","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":". From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.","volume":"104","author":"Kim","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R55-3-20210128","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neulet.2011.05.060","article-title":". AMP-activated protein kinase activates neuropeptide Y neurons in the hypothalamic arcuate nucleus to increase food intake in rats.","volume":"499","author":"Kohno","year":"2011","journal-title":"Neurosci Lett"},{"key":"R56-3-20210128","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","article-title":". The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.","volume":"112","author":"Cota","year":"2003","journal-title":"J Clin Invest"},{"key":"R57-3-20210128","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","article-title":". Leptin-regulated endocannabinoids are involved in maintaining food intake.","volume":"410","author":"Di Marzo","year":"2001","journal-title":"Nature"},{"key":"R58-3-20210128","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":". Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.","volume":"115","author":"Osei-Hyiaman","year":"2005","journal-title":"J Clin Invest"},{"key":"R59-3-20210128","doi-asserted-by":"crossref","first-page":"R345","DOI":"10.1152\/ajpregu.00545.2002","article-title":". Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.","volume":"284","author":"Ravinet Trillou","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R60-3-20210128","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/sj.ijo.0802583","article-title":". CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.","volume":"28","author":"Ravinet Trillou","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R61-3-20210128","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/sj.bjp.0704379","article-title":"Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats.","volume":"134","author":"Jamshidi","year":"2001","journal-title":"Br J Pharmacol"},{"key":"R62-3-20210128","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.neuropharm.2005.04.017","article-title":"Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus.","volume":"49","author":"Gamber","year":"2005","journal-title":"Neuropharmacology"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31827d145a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:00:53Z","timestamp":1620957653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201302000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31827d145a","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}